All In MedTech

Device Trial Radar · NCT06093100

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim

Wearable Technology to Evaluate Hyperglycemia and Heart Rate Variability in Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jul 10, 2024

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Male only, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in DMD, but substantial knowledge gaps exist regarding predisposing risk factors. In the general population, hyperglycemia, insulin resistance, and decreased heart rate variability (HRV; reflecting autonomic dysfunction) are associated with cardiomyopathy (CM). It is unclear whether these factors are associated with DMD-CM. Closing this knowledge gap may lead to novel screening and therapeutic strategies to delay progression of DMD related CM. Despite risk factors for hyperglycemia, including the use of glucocorticoids, low muscle mass, obesity, and reduced ambulation, little is known regarding glucose abnormalities in DMD. Some of these same risk factors, along with the distance needed to travel for specialty care, present significant barriers to research participation and clinical care for individuals with DMD. Remote wearable technology may improve research participation in this vulnerable population. Therefore, this study will leverage remote wearable technologies to overcome these barriers and define the relationship between dysglycemia and DMD-CM. In this Aim of the study, the investigators will assess the utility of remote wearable technology to predict changes in traditional metrics of metabolism and cardiac function. In this pilot study, 10 individuals with DMD will undergo cardiac magnetic resonance imaging (CMR) and oral glucose tolerance tests (OGTTs) at baseline and two years. The investigators will remotely assess glycemia (using continuous glucose monitors), HRV (using extended Holter monitors), and activity (using accelerometers) every 6 months over the 2 years and evaluate if changes in wearable metrics predict changes in CMR and OGTT.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • wearable technologyDevice

    Three wearable devices

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of hyperglycemiaTime frame: 5 time points, each over 10 days
  2. Standard deviation of the mean R-to-R segment (SDANN)Time frame: 5 time points, each over 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.